Pilot study of the safety and efficacy of quadrivalent human papillomavirus vaccine (Gardasil) in female subjects with juvenile idiopathic arthritis (JIA)/ seronegative arthritis.

Trial Profile

Pilot study of the safety and efficacy of quadrivalent human papillomavirus vaccine (Gardasil) in female subjects with juvenile idiopathic arthritis (JIA)/ seronegative arthritis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Acronyms CHASE
  • Most Recent Events

    • 13 Jun 2012 Additional lead investigators identified as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Planned end date changed from 1 Nov 2011 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top